33.93
2.61 (8.33%)
| Previous Close | 31.32 |
| Open | 31.61 |
| Volume | 474,217 |
| Avg. Volume (3M) | 1,106,617 |
| Market Cap | 2,025,684,864 |
| Price / Sales | 20.41 |
| Price / Book | 1.99 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | 1,798.26% |
| Operating Margin (TTM) | -1,221.97% |
| Diluted EPS (TTM) | 11.54 |
| Quarterly Revenue Growth (YOY) | 6.60% |
| Total Debt/Equity (MRQ) | 3.61% |
| Current Ratio (MRQ) | 18.50 |
| Operating Cash Flow (TTM) | -401.46 M |
| Levered Free Cash Flow (TTM) | -237.66 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | 60.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Agios Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 0.71 |
Select this tab to load the latest available analysis.
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.65% |
| % Held by Institutions | 101.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lynx1 Capital Management Lp | 30 Jun 2026 | 3,408,937 |
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,154,900 |
| Nomura Investment Management Business Trust | 30 Jun 2026 | 2,110,809 |
| Assenagon Asset Management S.A. | 30 Sep 2026 | 1,886,412 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |